Why are some of the new anti-Alzheimer’s antibodies better than others? With the FDA’s approval of Lecanemab and Donanemab, it’s worth staying on top of this topic’s latest research.
The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
A new Harvard study of 2,000 former NFL players shows one-third believe they have chronic traumatic encephalopathy (CTE), a neuropathological condition linked to repeated head trauma.
Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.
Kisunla, the newest Alzheimer’s drug, is rapidly gaining acceptance around the world. Learn what it does and how to get it.
How do the new drugs Leqembi and Kisunla fight Alzheimer’s? Surprisingly, increases in amyloid-beta protein levels can explain the slowing of Alzheimer’s at least as well as the reduction in amyloid plaques.
Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide
Diabetes and prediabetes are dementia risk factors. They affect 1 in 7 adults! Learn about new research to lower that risk with lifestyle and drugs.
There are no approved treatments for DLB, though it is the second most common type of dementia. Do drugs like donepezil hold the key?
In the USA, the same person may be twice as likely to be told they have dementia, depending on where they are diagnosed. Learn more to get a more accurate test and better treatment.
Here’s Teddy Mac and his son Simon singing Oklahoma – one of his showstoppers – from a few years ago.
This isn’t any ordinary garden! It’s home to a very special group of people living well with Alzheimer’s.
The Housing Learning and Improvement Network looks at the design process and philosophy behind creating a successful Extra Care scheme.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
No spam, only news and updates.
